Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
RLAY Relay Therapeutics
18.770
+0.990+5.57%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
-48.35% 344K -56.75% 365K -55.99% 419K -96.34% 3.03M
Operating revenue
-48.35% 344K -56.75% 365K -55.99% 419K -96.34% 3.03M
Cost of revenue
Gross profit
Operating expense
39.09% 82.97M 30.90% 77.98M 56.23% 67.74M 66.15% 230.04M
Selling and administrative expenses
9.48% 16.07M 21.10% 17.47M 26.17% 16.07M 48.71% 57.39M
-General and administrative expense
9.48% 16.07M 21.10% 17.47M 26.17% 16.07M 48.71% 57.39M
Research and development costs
48.75% 66.9M 34.03% 60.51M 68.73% 51.67M 72.89% 172.65M
Operating profit
-40.07% -82.63M -32.16% -77.61M -58.75% -67.32M -306.85% -227.01M
Net non-operating interest income expense
991.08% 1.71M 458.33% 1.01M 207.96% 696K -75.59% 830K
Non-operating interest income
991.08% 1.71M 458.33% 1.01M 207.96% 696K -75.59% 830K
Other net income (expense)
-62.75% -3.26M 99.87% -182K 91,580.00% 4.57M -860,493.75% -137.7M
Gain on sale of security
-63.10% -3.26M -- -200K -- 4.6M -- -2.84M
Special income (charges)
-- 0 -- 0 -- -- -- -134.86M
-Less:Restructuring and merger&acquisition
-- 0 -- 0 -- -- -- 11.86M
-Less:Other special charges
-- -- -- -- -- -- -- 123M
Other non- operating income (expenses)
-- 7K 1,700.00% 18K -320.00% -21K 75.00% -4K
Income before tax
-38.37% -84.17M 60.30% -76.79M -47.08% -62.05M -594.25% -363.87M
Income tax
Net income
-38.37% -84.17M 60.30% -76.79M -47.08% -62.05M -594.25% -363.87M
Net income continuous Operations
-38.37% -84.17M 60.30% -76.79M -47.08% -62.05M -594.25% -363.87M
Minority interest income
Net income attributable to the parent company
-38.37% -84.17M 60.30% -76.79M -47.08% -62.05M -594.25% -363.87M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-38.37% -84.17M 60.30% -76.79M -47.08% -62.05M -58.07% -363.87M
Basic earnings per share
-15.15% -0.76 66.19% -0.71 -21.28% -0.57 29.26% -3.82
Diluted earnings per share
-15.15% -0.76 66.19% -0.71 -21.28% -0.57 29.26% -3.82
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.
CEO: Mr. Sanjiv K. Patel, M.D.
Market: NASDAQ
Listing Date: 07/16/2020
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist